We are committed to being a socially responsible and sustainable company
by listening to our stakeholders’ voices and understanding what their expectations are.
Samsung Bioepis is committed to pursuing sustainability management with a focus on ESG(Environment, Social, and Governance). We plan to share our yearly achievements and activities transparently through our annual report, and enhance the effectiveness of our sustainability management by gathering our various stakeholders' opinions and reflecting them.
Samsung Bioepis selects suppliers according to strict criteria aimed at building and operating a responsible supply chain, and they are managed through a transparent registration system. For CMOs in particular, we carefully select companies that have obtained international standard (ISO) certification for their environmental management, energy management, and occupational health and safety management systems, verifying that they systematically practice environmental and safety management. Going a step further, we are reviewing the introduction of a policy for the preferential use of eco-friendly transportation as a way of governing the environmental impact of our supply chain. We are also discussing the use of additional ESG evaluation items in our processes for supplier selection, regular evaluations, and contract renewal.
Supply Chain Assessment
Samsung Bioepis established supply chain assessment process for ESG risk management and conducted the pilot assessment of major suppliers in 2022. Going forward, we plan to manage supply chain risks that are related to ethics, human rights, labor, environment, safety and health, by gradually increasing the number of suppliers assessed for their risk management.
Based on the results of the supply chain assessment, Samsung Bioepis can recommend improvements for identified high risks to the extent not in violation of laws and regulations. In response, the suppliers shall develop a plan based on mutual consultation and take implementation actions.
Code of Conduct and Checklist
Analyze a result
|Classification||New Supplier Assessment||Regular Assessment|
|Target||New Supplier||Existing Suppliers|
|Period||When registering a new supplier||Annually|
10 Compliance criteria that include ethics,
human rights, labor, environment,
and Health & Safety
|55 criteria of overall ESG management|
Suppliers who have worked with less than
Suppliers who have worked with 2 years
Key Service Providers such as CMO and CRO
Key Material Suppliers
By increasing market competition, biosimilars have become an important lever for the innovation of next generation biologics. While our focus remains on the development of high-quality biosimilars, we are now taking our first steps into novel biologic development. We are also looking to enhance the patient experience, including the development of ergonomic autoinjector devices and extended storage conditions for our products.
At Samsung Bioepis, we have established environmental management principles and systems adhered to the green management philosophy, which we are practicing across the company. As an R&D company with low energy consumption, we are not subject to targets for Greenhouse Gas (GHG) emissions and energy consumption. Nonetheless, we are continuing our proactive efforts to save energy and reduce emissions. Furthermore, we have put in place a management system for water resources, waste, air pollutants and hazardous chemicals, and we are introducing eco-friendly packaging materials as part of building a circular economy and enhancing resource efficiency.
We have established our systematic management processes by implementing ISO 14001 (Environmental Management System) and ISO 15001 (Energy Management System). With having those processes and systems in place, we are committed to making ongoing efforts to minimize environmental risks and impacts.
As the largest source of Samsung Bioepis’s greenhouse gas (GHG) emissions is from electricity consumption, increasing the use of renewable energy is crucial to reduce GHG emissions. In reflection of our commitment, we joined RE100, a global corporate initiative to run on Renewable Energy 100%, in November 2022. We will continue our efforts to cut GHG emissions.
As a global biopharmaceutical company, Samsung Bioepis respects the human rights of all stakeholders involved in our business activities. We respect international human rights principles outlined in the Universal Declaration of Human Rights (UDHR), the UN Guiding Principles on Business and Human Rights (UNGPs), the OECD multinational business guidelines, the UN Convention on the Rights of the Child, the Core Conventions of the International Labor Organization (ILO), and Corporate Human Rights Benchmark (CHRB), as well as the local and national labor and human rights laws governing the locations in which we conduct business.
Samsung Bioepis prioritizes securing the safety and health of customers, employees, and community while we comply with rule & process to prevent accidents and to protect environment, and practice compliance management.
Recognizing that safety, health and environmental protection are of the utmost value and should not be compromised in any circumstances for corporate sustainability management, Samsung Bioepis will :
Encourage executives to continuously demonstrate leadership and commitment to ESH management.
Communicate the values and objectives of ESH management to ensure that they are put into action company-wide with all employees and cooperative firms (CMO, CRO, Marketing Partner, cooperative firms for infra management and so on).
Ensure all employees and cooperative firms actively comply with the rule & process to prevent accidents and to protect environment.
Ensure elimination of hazards, and reduction of safety and health risks prior to any work and create safe, healthy and pleasant working environment and make effort for continuous improvement.
Continue to put in best efforts to minimize the release of GHG
As a biopharmaceutical company, all of our products are biologic medicines which are similar to proteins in nature. The active pharmaceutical ingredients of our products are non-hazardous, biodegradable, mainly consisting of amino acids / proteins / carbohydrates. Based on these characteristics, our products will go through rapid and extensive degradation, that will minimally result in a significant environmental risk.
As a global biopharmaceutical company, Samsung Bioepis pursues its business strategy that incorporates both economic and wider social values across its business activities.
In addition, securing a sustainable supply chain will enable us to strengthen our purchasing competitiveness and risk management capabilities while helping us to establish appropriate monitoring system. We have established the Purchasing Code of Ethics, Purchasing Management Regulations, and Supply Chain Assessment Regulations to create a transparent and fair trade environment, and also to better manage the potential risk in our supply chain.